Search results
Showing 6136 to 6150 of 7707 results
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
A safe space for bold ideas – implementing a sandbox approach in health technology assessment
Colleagues in our Science Policy and Research Programme discuss their international research, paving the way for next generation health technology assessment.
Two technologies recommended for people with chronic tic disorders and Tourette syndrome
Draft guidance issued for consultation recommends two technologies to help people manage their condition.
5 ways NICE Advice can help you navigate this new opportunity alongside health technology assessment.
New study shows NICE Advice support can reduce appraisal timelines by 3 months
Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.
We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.
If you have any queries, please contact nice@nice.org.uk.
Process guide for adoption support resources for health technologies (PMG23)
This process and methods guide has been withdrawn.
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.
We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.
If you have any queries, please contact nice@nice.org.uk.
This guidance has been updated and replaced by NICE diagnostics guidance 44.
This guidance has been updated and replaced by NICE guideline NG130.
Myocardial infarction with ST-segment elevation: acute management (CG167)
This guideline has been updated and replaced by NICE guideline NG185.